SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as traders assess its AI dominance amid competition, potential China trade risks, and recent product developments. Community members are actively discussing chart patterns, potential breakouts, and whether the stock remains a top AI play. Sentiment is mixed, with some highlighting new partnerships while others express concerns about valuation and market saturation.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSIT is surging due to a published paper highlighting its APU's comparable performance to NVIDIA GPUs with significantly lower energy consumption, sparking community excitement. Traders are discussing the potential for buyouts and disruption in the AI chip market given the impressive energy efficiency. The community is closely watching for continuation and potential short squeezes.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the community assesses the impact of a recently revealed lawsuit from GIC, with many dismissing it as old news and accusing short-sellers of manipulation. Bulls are highlighting the company's potential for growth, pointing to strong delivery numbers for ONVO and overall production capacity. Despite some volatility, investors are closely watching for any signs of profitability and a potential rebound.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending amid anticipation for data from its Phase III HARMONi trial at the World Conference on Lung Cancer, with bullish investors hoping for strong overall survival results for its lung cancer drug, ivonescimab. Community members are actively debating the drug's potential to compete with Keytruda and the implications of regional differences in trial outcomes, while some analysts maintain high price targets.

Aster is a next-generation decentralized exchange offering both Perpetual and Spot trading, designed as a one-stop onchain venue for global crypto traders. It features MEV-free, one-click execution in Simple Mode. Pro Mode adds 24/7 stock perpetuals, Hidden Orders, and grid trading, available across BNB Chain, Ethereum, Solana, and Arbitrum.  Its unique edge lies in the ability to offer liquid-staking tokens (asBNB) or yield-generating stablecoins (USDF) as collateral, unlocking unparalleled capital efficiency. Powered by Aster Chain, a high-performance and privacy-focused L1, and backed by YZi Labs, Aster is building the future of DeFi: fast, flexible, and community-first.  At the heart of this ecosystem is the $ASTER token, a core asset that decentralizes governance, drives growth, rewards participation, and supports long-term sustainability.

ASTERION

ASTERION ($ASTER) is seeing heightened interest, with community members actively discussing its recent performance and potential catalysts like Robinhood listing rumors. Technical analysis suggests possible bullish patterns, though some traders caution against potential pullbacks and volatility. The coin's connection to Binance and CZ is a recurring theme, with mentions of both positive endorsements and concerns about market manipulation.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending due to news of a potential expansion into rare earth mineral production, sparking excitement and speculation about the company's strategic shift. Community discussions revolve around the implications of this move, with some questioning the feasibility and cost-effectiveness of extracting rare earth minerals from iron ore, while others see it as a game-changer for U.S. strategic metals and a potential re-rating of the stock.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors discuss the potential impact of recent investments and a pending BFS release, with community members speculating on who acquired a significant stake in the company. Conversations also highlight the company's strategic positioning amid the US-Australia partnership for rare earth elements and critical minerals, with some seeing the stock as undervalued while others express concern over market manipulation.

The Mosaic Co. engages in the production and marketing of concentrated phosphate and potash crop nutrients. It operates through the following segments: Phosphates, Potash, and Mosaic Fertilizantes. The Phosphates segment is involved in the ownership and operation of mines and production facilities which produce concentrated phosphate crop nutrients and phosphate-based animal feed ingredients, and processing plants which produce concentrated phosphate crop nutrients. The Potash segment includes mining, processing, and selling potash. The Mosaic Fertilizantes segment focuses on mines, chemical plants, crop nutrient blending and bagging facilities, port terminals, and warehouses. The company was founded on March 25, 2004 and is headquartered in Tampa, FL.

Mosaic Company

Mosaic is trending as investors discuss its valuation and potential catalysts, including production cuts from competitors and the impact of geopolitical events. The community is weighing the company's recent performance against its long-term potential in the fertilizer market, particularly as a value play. Some are speculating on a potential takeover given its low valuation compared to its book value.

Grayscale Ethereum Trust (ETH) operates as open-end investment company. Its investment objective is for the shares to reflect the value of ETH held by the trust. The company was founded on December 13, 2017 and is headquartered in Stamford, CT.

Grayscale Ethereum Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Ethereum Mini Trust

Grayscale Ethereum Mini Trust is trending as investors react to fee cuts, positioning it as one of the cheapest Ethereum ETFs. Community discussions revolve around accumulation strategies, potential price targets, and the broader implications of institutional adoption of ETH. Market participants are also watching for signals suggesting ETH's potential to outperform Bitcoin.

Cheesecake Factory, Inc. engages in the operation of restaurant chains. It operates through the following segments: The Cheesecake Factory Restaurants, North Italia, Other FRC, and Other. The Cheesecake Factory Restaurants segment offers appetizers, pizza, seafood, steaks, chicken, burgers, small plates, pastas, salads, sandwiches and omelettes, and a selection of gluten-free items. The North Italia segment specializes in Italian cuisine. The Other FRC segment includes brands acquired from Fox Restaurant Concepts. The Other segment consists of the Flower Child brand, along with other businesses. The company was founded by David M. Overton, Oscar Overton, and Evelyn Overton in 1972 and is headquartered in Calabasas Hills, CA.

Cheesecake Factory Inc.

Cheesecake Factory ($CAKE) is trending due to recent analyst rating updates and community discussion around earnings, revenue, and expansion plans. Community members are actively discussing price targets and potential short squeezes, highlighting the stock's high short interest. The conversation also includes the company's growth potential through its Flower Child and North Italia brands, as well as its position within the broader casual dining sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?

Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of 0.00% and +14.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: Should You Buy?

Aclaris (ACRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates

Aclaris Therapeutics ($ACRS) stock rose more than 46% on Tuesday after the clinical-stage biopharmaceutical company entered into a licensing deal with Biosion for rights for two antibody products and announced an $80 million funding, lifting retail sentiment.Aclaris is focused on developing drugs to treat immuno-inflammatory diseases. The exclusive license agreement with Biosion includes worldwide rights (excluding Greater China) to BSI-045B, a clinical-stage, novel anti-TSLP monoclonal antibody; and BSI-502, a pre-clinical stage novel bispecific antibody directed against “both TSLP and IL4R,” used to treat conditions like atopic dermatitis. &nbsp;The private placement includes over 35.55 million shares of common stock at a purchase price of $2.25 per share. The placement is expected to close on or about Nov. 19, 2024, subject to customary closing conditions.Vivo Capital led the funding, with participation from new and existing investors including Forge Life Science Partners, Rock Springs Capital, RA Capital Management, Adage Capital Partners LP, Decheng Capital, Logos Capital and Samsara BioCapital.Several brokerages have revised their ratings for Aclaris following the news. Leerink upgraded Aclaris to ‘Outperform’ from ‘Market Perform’ with its price target raised to $7 from $2. The firm cited completion of the company's strategic review, and expects investor focus to shift to its "newly strengthened" immunology-focused pipeline that includes the two in-licensed biologics from discovery-focused Biosion - BSI-045B and BSI-502, The Fly.com <a target="_blank" rel="noopener noreferrer nofollow" href="https://thefly.com/">reported.</a>Jefferies also upgraded Aclaris to ‘Buy’ from ‘Hold’ with a price target of $7, up from $2.Meanwhile, Piper Sandler upgraded the company to ‘Overweight’ from ‘Neutral’ with a price target of $13, up from $3.Retail sentiment moved from ‘neutral’ (47/100) to ‘extremely bullish’(96/100); message volumes rose to ‘extremely high’ levels from ‘normal’.<figure class="image"><img style="aspect-ratio:1304/290;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_19_at_9_24_37_PM_b73837e53c.png" alt="Screenshot 2024-11-19 at 9.24.37 PM.png" width="1304" height="290"><figcaption>ACRS sentiment and message volumes on Nov 19 as of 10:55 am ET| Source: Stocktwits</figcaption></figure>“This transformative transaction, which marks the completion of our strategic review process, accelerates our evolution into becoming a leading immunology company with both small and large molecule drugs," Neal Walker, interim CEO and chair of Aclaris, said in a statement.Net proceeds from the capital raise are expected to fund the research and development of its drug pipeline and for general corporate purposes.Aclaris stock is up 300% year-to-date.For updates and corrections, email newsroom@stocktwits.com &nbsp;&nbsp;

Net proceeds from the capital raise are expected to fund the research and development of its drug pipeline| Picture source: pexels

Aclaris Therapeutics Stock Surges On Licensing Deal, $80 Million Private Placement: Retail Sentiment Jumps

Leerink upgraded Aclaris to ‘Outperform’ from ‘Market Perform’ with its price target raised to $7 from $2; Piper Sandler upgraded the company  to ‘Overweight’ from ‘Neutral.’ 

Equity

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets Biosion Announces Exclusive, Global License...

H.C. Wainwright Reaffirms Their Hold Rating on Aclaris Therapeutics (ACRS)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Aclaris Therapeutics (ACRS Research Report). The compa...

Aclaris Therapeutics Secures Deal with OMERS for OLUMIANT Royalties

Aclaris Therapeutics (ACRS) has provided an update. Aclaris Therapeutics has struck a lucrative deal with OMERS, selling a portion of its future ro...

Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buying

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Aclaris Therapeutics Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$2.01
Prev Close	$1.90
Open	$1.97
Dividend Yield	0.00%
50-Day Moving Average	$1.89
Beta	1.14
Avg. Volume	1.09M
PE Ratio	-1.47

52-Week High	$5.17
52-Week Low	$1.05
Market Capitalization	$217.75M
EPS (Annual)	-$1.71
Price to Book	1.65
Revenue Per Employee	$292,500.00
Enterprise Value/EBITDA	N/A

ACRS
Aclaris Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACRS News

ACRSAclaris Therapeutics Inc